Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents
Authors
Keywords
-
Journal
International Journal of Clinical Pharmacy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-07
DOI
10.1007/s11096-020-01089-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coumarin: a novel player in microbial quorum sensing and biofilm formation inhibition
- (2018) F. Jerry Reen et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation
- (2018) Stephanie N Taylor et al. CLINICAL INFECTIOUS DISEASES
- Phenylthiazoles with tert -Butyl side chain: Metabolically stable with anti-biofilm activity
- (2018) Ahmed Kotb et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Murepavadin: a new antibiotic class in the pipeline
- (2018) Ignacio Martin-Loeches et al. Expert Review of Anti-Infective Therapy
- Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually
- (2018) Kenneth E. Thorpe et al. HEALTH AFFAIRS
- Evaluating the anti -biofilm and antibacterial effects of Juglans regia L. extracts against clinical isolates of Pseudomonas aeruginosa
- (2018) Samaneh Dolatabadi et al. MICROBIAL PATHOGENESIS
- Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
- (2018) Eili Y. Klein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
- (2017) Thomas F. Durand-Réville et al. Nature Microbiology
- In VitroActivity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens
- (2016) D. J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A review of global initiatives to fight antibiotic resistance and recent antibiotics׳ discovery
- (2016) Arpana Sagwal Chaudhary Acta Pharmaceutica Sinica B
- In VitroActivity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The global challenge of new classes of antibacterial agents: an industry perspective
- (2015) Prabhavathi Fernandes CURRENT OPINION IN PHARMACOLOGY
- Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases
- (2015) Gregory S. Basarab et al. Scientific Reports
- RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition
- (2015) Henrietta Venter et al. Frontiers in Microbiology
- Combating multidrug-resistant Gram-negative bacterial infections
- (2013) Ze-Qi Xu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Antimicrobial resistance: action to combat the rising microbial challenges
- (2013) Niki I. Paphitou INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Novel classes of antibiotics or more of the same?
- (2011) Anthony RM Coates et al. BRITISH JOURNAL OF PHARMACOLOGY
- Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
- (2011) CLINICAL INFECTIOUS DISEASES
- Type IIA topoisomerase inhibition by a new class of antibacterial agents
- (2010) Benjamin D. Bax et al. NATURE
- The global need for effective antibiotics: challenges and recent advances
- (2010) Liselotte Diaz Högberg et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started